Shuhao Wen
温书豪
Shuhao Wen is a Chinese scientist-entrepreneur who co-founded and chairs XtalPi (晶泰科技), an AI-driven drug discovery company. He established the firm in 2014 alongside Lipeng Lai and Jian Ma while conducting postdoctoral research at MIT, with a stated vision of letting "AI flow into every new drug" . The company went public in 2024 . Beyond his role at XtalPi, where he has served variously as co-founder, chairman, and board chairman , Wen holds an adjunct professorship at Zhejiang University and earned his PhD from the Chinese Academy of Sciences before pursuing postdoctoral work at UC and MIT . 5Y Capital, an early backer of ITBT ventures, has been among the investors in his orbit .
AI-generated — may contain errors, please verify.
Coverage
On the Eve of IPO, a Conversation with METiS Pharmaceuticals' Caida Lai: From Formulas on a Whiteboard to "The SpaceX of Pharma"
The story behind the investment.
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
Congratulations to FengRui's early-stage portfolio company Lightelligence on its successful IPO: From a Boston Dining Table to Photonic Infrastructure for the AI Era
The World's First Publicly Traded AI Silicon Photonics Chip Company
Five Sources Capital Promotes Its First Post-90s Partner
How Do VCs Grow New Capabilities?
2025: Three Directions Where AI Is Reshaping Drug Discovery
How Can AI Help Drug Development Cross the "Valley of Death"?
January: Arriving at the Realm of Infinity | 5Y News Monthly
The big news from last month.
Seeking Entrepreneurs for the Era of Tech Innovation 2.0 | 2024 5Y Capital USD Fund Partner Meeting Recap
They don't just have cross-disciplinary technical integration capabilities — they also bring a global perspective.
5Y News | 5Y Capital Portfolio Company ReviR Therapeutics Raises $30 Million in Series A Funding
Continuing to advance "oral gene therapy" through AI+RNA.
5Y News | 5Y Capital Portfolio Company "Laimang Biotech" Raises 50 Million Yuan in New Funding
Accelerating the clinical translation of ultra-low-dose CAR-T.
Congratulations to XtalPi on its successful listing on the Hong Kong Stock Exchange! | 5Y News
"AI + Robotics" builds the first 18C-listed stock, constructing new R&D infrastructure for future industries.
Congratulations to XtalPi on its Successful IPO: How FreeS Fund's Research-Driven Approach Learns from Investing
AI + Robotics Creates First 18C Listing — Congratulations to XtalPi
Action Is the Simplest Method | 5Y News Monthly
The big news from last month.
What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
From Tech to Business: New Possibilities Brought by ITBT | 5Y Talk
We spoke with five entrepreneurs about their progress and breakthroughs.
5Y News | Limmuno Biotech Closes Nearly RMB 100 Million Angel Round
Immunometabolic Reprogramming + AI-Powered Computation for Innovative Cancer Immunotherapy
Morningside-backed XtalPi raises over $300 million in new funding | Light Moments
5Y Capital has long been bullish on the application of computational science in the life sciences, hoping that the convergence of IT and biotechnology will soon usher human health into a new era.
FreeS Fund received eight recognitions from institutions including *Fortune* (Chinese edition), 36Kr, and the Fund of Funds Alliance.
Do what's right, not what's easy.
AI-powered pharmaceutical formulation development company "METiS" announced the completion of a multi-million dollar angel round — Source Code Capital participated as a follow-on investor.
The world's first startup to use AI to drive pharmaceutical formulation development, dedicated to providing drug companies with rapid, precise intelligent formulation R&D through high-throughput formulation platforms and AI computing technologies.
Harvard x MIT x Stanford x CMU x Berkeley, Meeting Gen Z | FreeS Fund North America Campus Recruitment
Welcome aboard. Join the innovators and build something new.
XtalPi Closes $46 Million Series B+ Round | FreeS Fund Deal Brief
Empowering drug R&D organizations worldwide.
A Founder's 365 Days: The Days That Got Us Through, and 22 Amazing Moments | FreeS Fund Year-End Special
Here's to exploration, struggle, and perseverance. Happy New Year!
